Sinco Pharma
Sinco Pharma, a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a key provider of high-quality pharmaceutical products, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. With a commitment to innovation and quality, Sinco Pharma offers a diverse range of products, including generic medications and custom synthesis services, which are distinguished by their rigorous quality control and compliance with international standards. The company has achieved significant milestones, including certifications from major regulatory bodies, solidifying its market position as a trusted supplier in the global pharmaceutical landscape. Sinco Pharma continues to expand its reach, driven by a dedication to enhancing healthcare outcomes worldwide.
DitchCarbon Score
How does Sinco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinco Pharma's score of 19 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sinco Pharma's reported carbon emissions
In 2022, Sinco Pharma reported total carbon emissions of approximately 300,710 kg CO2e, encompassing Scope 1, 2, and 3 emissions. Specifically, their emissions breakdown includes about 93,260 kg CO2e from Scope 1 (mobile combustion), approximately 171,420 kg CO2e from Scope 2 (purchased electricity), and around 64,170 kg CO2e from Scope 3, which includes business travel and waste generated in operations. Despite the significant emissions, Sinco Pharma has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of formal climate pledges or science-based targets indicates a need for further commitment to sustainability practices within the pharmaceutical industry. As a company headquartered in China, Sinco Pharma is positioned within a rapidly evolving landscape of corporate climate responsibility, where increasing pressure exists to enhance transparency and accountability regarding carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 93,260 |
| Scope 2 | 171,420 |
| Scope 3 | 67,030 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinco Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
